Home › Lupus Nephritis
Lupus Nephritis clinical trials recruiting in the U.S.
34 studies for Lupus Nephritis are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Chicago, IL9 studies
- Durham, NC9 studies
- Houston, TX8 studies
- Boston, MA7 studies
- San Francisco, CA7 studies
- Philadelphia, PA6 studies
- St. Louis, MO5 studies
- Miami, FL5 studies
- Dallas, TX4 studies
- Gainesville, FL4 studies
- Syracuse, NY4 studies
- Charleston, SC4 studies
- Aurora, CO4 studies
- Charlotte, NC4 studies
- Washington, DC3 studies
- Columbus, OH3 studies
- Johns Creek, GA3 studies
- Cincinnati, OH3 studies
- Worcester, MA3 studies
- Los Angeles, CA3 studies
- Baltimore, MD3 studies
- Jacksonville, FL3 studies
- Cleveland, OH3 studies
- Santa Monica, CA3 studies
By state
- Arizona3 studies
- California14 studies
- Colorado6 studies
- Florida11 studies
- Georgia11 studies
- Illinois9 studies
- Louisiana4 studies
- Maryland5 studies
- Massachusetts8 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri6 studies
- New Jersey5 studies
- New York15 studies
- North Carolina12 studies
- Ohio7 studies
- Pennsylvania6 studies
- South Carolina5 studies
- Tennessee4 studies
- Texas11 studies
Recently updated studies
Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study
RecruitingObservational study
Up to age 18 · All sexes · Updated Nov 12, 2026 · NCT07931170Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 9, 2026 · NCT06711887Dapagliflozin in Active Lupus Nephritis
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Nov 6, 2026 · NCT07323524Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06434363A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
RecruitingPhase 2
Ages 5 to 17 · All sexes · Updated Nov 3, 2026 · NCT05039619A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Nov 2, 2026 · NCT07085104Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
RecruitingPhase 2
Ages 12 to 65 · All sexes · Updated Oct 30, 2026 · NCT07053800Study of Systemic Lupus Erythematosus
RecruitingObservational studyHealthy volunteers welcome
Ages 3 to 120 · All sexes · Updated Oct 29, 2026 · NCT00001372Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Oct 27, 2026 · NCT06975787A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT06925542Lupus Nephritis Care Pathway
Recruiting
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07783152RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
Ages 12 to 65 · All sexes · Updated Oct 6, 2026 · NCT06121297A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
RecruitingPhase 2
Ages 16 and older · All sexes · Updated Oct 1, 2026 · NCT06419205CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RecruitingPhase 1/2
Ages 10 to 29 · All sexes · Updated Sep 24, 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RecruitingPhase 2
Ages 8 to 20 · All sexes · Updated Sep 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
RecruitingPhase 2
Ages 12 to 70 · All sexes · Updated Sep 14, 2026 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
RecruitingPhase 4
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT07611214A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 30, 2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
RecruitingHealthy volunteers welcome
Ages 18 and older · Women · Updated Jul 24, 2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT06527872US Zamto-cel Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06708845From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.